Clinical Trials Logo

Clinical Trial Summary

This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic retinopathy.


Clinical Trial Description

This study is to prove that Entelon tab. 50mg is superior in clinical efficacy and safety compared to placebo for 24 months in patients suffering from non-proliferative diabetic retinopathy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05358080
Study type Interventional
Source Hanlim Pharm. Co., Ltd.
Contact Ha Kyoung Kim
Phone 82-2-6960-1240
Email ophkim@hallym.or.kr
Status Recruiting
Phase Phase 4
Start date May 27, 2022
Completion date December 16, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT01921192 - Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Phase 4
Completed NCT01145599 - Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures N/A
Terminated NCT00563043 - Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Phase 4
Terminated NCT00563628 - Changes in Macular Thickness After Patterns Scan Laser Phase 4
Active, not recruiting NCT03597815 - Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study
Recruiting NCT04103671 - Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR N/A